Since the combination of an AAV9 serotype vector with a constitutive promoter (such as GUSB) fulfills the criteria for neurological and visceral expression, this combination has been widely used in clinical trials of gene therapy to treat neurological disorders [99] and other LSDs [100] and in pre-clinical trials for GD [50,70]. The gene discussed is GUSB; the disease is nervous system disorder.